✦ LIBER ✦

Interferon-α and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials

✍ Scribed by Ulrich Keilholz; Carmen Scheibenbogen; Wolfgang Tilgen; Lothar Bergmann; Eckardt Weidmann; Evi Seither; Max Richter; Bernadett Brado; Paris S. Mitrou; Werner Hunstein

Book ID: 118280972
Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 671 KB
Volume: 72
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19930715)72:2<607::aid-cncr2820720245>3.0.co;2-r

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of recombinant human inte

Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: Implications for the treatment of patients with metastatic melanoma

✍ Omar Eton; Moshe Talpaz; Kyoo H. Lee; Jeanne M. Rothberg; Joanna M. Brell; Rober 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 664 KB

Ambulatory treatment of metastatic melan

Ambulatory treatment of metastatic melanoma associating subcutaneous dacarbazine, interferon α and interleukin-2

✍ B. Dréno; D. Cupissol; P. Joly; B. Sassolas; T. Bonneterre; J.M. Tourani 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 451 KB

Final report of a phase II study of inte

Final report of a phase II study of interleukin 2 and interferon α in patients with metastatic melanoma

✍ Kruit, WHJ; Goey, SH; Calabresi, F; Lindemann, A; Stahel, RA; Poliwoda, H; Oster 📂 Article 📅 1995 🏛 Nature Publishing Group 🌐 English ⚖ 507 KB

A phase II study of dacarbazine, cisplat

A phase II study of dacarbazine, cisplatin, interferon-α and high-dose interleukin-2 in ‘poor-risk’ metastatic melanoma

✍ T.M. Proebstle; C. Scheibenbogen; W. Sterry; U. Keilholz 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 452 KB

A Phase II study of “decrescendo” interl

A Phase II study of “decrescendo” interleukin-2 plus interferon-α-2a in patients with progressive metastatic melanoma after chemotherapy

✍ Omar Eton; Antonio C. Buzaid; Agop Y. Bedikian; Teresa M. Smith; Nicholas E. Pap 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

The authors tested a biotherapy regimen involving recombinant interferon-␣-2a (rIFN-␣-2a) and recombinant human interleukin-2 (rhIL-2), given in a "decrescendo" schedule over 5 days, for its activity and toxicity in 21 patients who previously had received chemotherapy for advanced melanoma. ## METH

Phase II study of temozolomide plus pegy

Phase II study of temozolomide plus pegylated interferon-α-2b for metastatic melanoma

✍ Wen-Jen Hwu; Katherine S. Panageas; Jennifer H. Menell; Lynne A. Lamb; Suzan Air 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB